Phase II study of combination human recombinant GM‐CSF with intermediate‐dose cytarabine and mitoxantrone chemotherapy in patients with high‐risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study